Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical nee…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term clinical catalysts during a presentation at the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference. Chief Executive Officer Riccardo Canevari described the compa | ||
 Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs Radiopharm Theranostics ADR (NASDAQ:RADX) is among the best Australian stocks to buy in 2026. Radiopharm Theranostics ADR (NASDAQ:RADX) continues to advance its clinical programs with solid results. On April 20, the company presented initial findings from an early-stage trial of its cancer drug candidate at the American Association for Cancer Research Annual Meeting. The drug […] | IInsider Monkey | |
 Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase 1 clinical trial of its lead prostate cancer candidate RAD 402, marking the company’s entry into first-in-human studies for the program. The trial is evaluating RAD 402 in patients with... | ||
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company’s ongoing Phase IIb study of RAD101, a PET imaging tracer intended to help physicians evaluate suspected recurrent brain metastases after radiotherapy when MRI results are un | ||
Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks Radiopharm Theranostics (NASDAQ:RADX) provided an update on its clinical-stage radiopharmaceutical pipeline during an investor conference presentation led by CEO Riccardo Canevari, highlighting interim results from its lead imaging program and progress across four therapeutic candidates in human tri | ||
 Favourable Signals For Radiopharm Theranostics: Numerous Insiders Acquired Stock Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... | ||
 Radiopharm (RADX) Sees Slight Pessimism From Analysts We recently published 7 Best ASX Stocks to Buy Right Now. Radiopharm Theranostics Limited (NASDAQ:RADX) is one of the best ASX stocks. Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company developing treatments for ailments such as brain metastasis and prostate cancer. B. Riley lowered its share price target for the firm to $13 from $15 and […] | IInsider Monkey | |
Top Midday Gainers Radiopharm Theranostics (RADX) said Monday that interim data from its phase 2b clinical trial of RAD | MMT Newswires | |
Radiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell Radiopharm Theranostics (RADX) shares were down over 15% in recent Monday premarket activity after t | MMT Newswires | |
 Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial Radiopharm (RADX) Theranostics announced that it has received a positive recommendation from the Data Safety and Monitoring Committee to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202, to the next dose level of 75mCi in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2-positive advanced solid tumors. The DSMC is a multidisciplinary committee that conducts detailed reviews of study data, discusses potential safety events and provides reco | ||